Octopus Ventures led the Series A round to support the company growth plans.
"We believe that information should sit at the very heart of an agent’s prospecting, marketing, and customer service and it was this vision that Octopus shared with us immediately. Our unique way of interpreting and processing data into usable information with straightforward tools allows estate agents to support their clients with finding their dream homes in record time. And that results in more instructions and many more satisfied clients. This major investment is a key stage in our exciting journey towards transforming the way estate agents do business."
The Manchester based educational technology start-up secured the capital from Greater Manchester Combined Authority and five regional private investors.
"We’re thrilled to have secured the funding which will allow us to continue operating for at least the next 15 months. We’ve got ambitious targets for growth, including content and app development, and this funding is vital to helping us in the next stage of our journey."
The Series B round was led by Eclipse Ventures with participation from a broad group of global financial and strategic backers.
"We were the first team to develop the scientific breakthroughs in deep learning to build autonomous driving technology that can easily scale to new markets using a data-learned approach. Today, we have all of the pieces in place to take what we have pioneered and drive AV2.0 forward. We have brought together world-class strategic partners in transportation, grocery delivery and compute, along with the best capital resources to scale our core autonomy platform, trial products with our commercial fleet partners, and build the infrastructure to scale AV2.0 globally."
Novalis LifeSciences led the Series B round, which will fund team expansion and platform commercialisation.
"Our mission as a company is to enable widespread patient access to life saving cell and gene therapies. One of the biggest obstacles to achieving this is cell and gene therapy manufacturing processes that are too expensive, too highly variable and too low throughput. Our team is focused on the urgent need to enhance the ability of cell and gene therapy developers, CDMOs and Academic Medical Centers to deliver these therapies to as many patients as possible as quickly as possible,"
